Human Menstrual Blood-Derived Mesenchymal Stem Cells as Potential Cell Carriers for Oncolytic Adenovirus

Antitumor efficacy of systemically administered oncolytic adenoviruses (OAdv) is limited due to diverse factors such as liver sequestration, neutralizing interactions in blood, elimination by the immune system, and physical barriers in tumors. It is therefore of clinical relevance to improve OAdv bi...

Full description

Saved in:
Bibliographic Details
Main Authors: R. Moreno, L. A. Rojas, Felip Vilardell Villellas, Vanessa Cervera Soriano, J. García-Castro, C. A. Fajardo, R. Alemany
Format: Article
Language:English
Published: Wiley 2017-01-01
Series:Stem Cells International
Online Access:http://dx.doi.org/10.1155/2017/3615729
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850166728193998848
author R. Moreno
L. A. Rojas
Felip Vilardell Villellas
Vanessa Cervera Soriano
J. García-Castro
C. A. Fajardo
R. Alemany
author_facet R. Moreno
L. A. Rojas
Felip Vilardell Villellas
Vanessa Cervera Soriano
J. García-Castro
C. A. Fajardo
R. Alemany
author_sort R. Moreno
collection DOAJ
description Antitumor efficacy of systemically administered oncolytic adenoviruses (OAdv) is limited due to diverse factors such as liver sequestration, neutralizing interactions in blood, elimination by the immune system, and physical barriers in tumors. It is therefore of clinical relevance to improve OAdv bioavailability and tumor delivery. Among the variety of tumor-targeting strategies, the use of stem cells and specifically bone marrow-derived mesenchymal stem cells (BM-MSCs) is of particular interest due to their tumor tropism and immunomodulatory properties. Nonetheless, the invasive methods to obtain these cells, the low number of MSCs present in the bone marrow, and their restricted in vitro expansion represent major obstacles for their use in cancer treatments, pointing out the necessity to identify an alternative source of MSCs. Here, we have evaluated the use of menstrual blood-derived mesenchymal stem cells (MenSCs) as cell carriers for regional delivery of an OAdv in the tumor. Our results indicate that MenSCs can be isolated without invasive methods, they have an increased proliferation rate compared to BM-MSCs, and they can be efficiently infected with different serotype 5-based capsid-modified adenoviruses, leading to viral replication and release. In addition, our in vivo studies confirmed the tumor-homing properties of MenSCs after regional administration.
format Article
id doaj-art-de6f1c4234784439b0c21ffd67a754bc
institution OA Journals
issn 1687-966X
1687-9678
language English
publishDate 2017-01-01
publisher Wiley
record_format Article
series Stem Cells International
spelling doaj-art-de6f1c4234784439b0c21ffd67a754bc2025-08-20T02:21:21ZengWileyStem Cells International1687-966X1687-96782017-01-01201710.1155/2017/36157293615729Human Menstrual Blood-Derived Mesenchymal Stem Cells as Potential Cell Carriers for Oncolytic AdenovirusR. Moreno0L. A. Rojas1Felip Vilardell Villellas2Vanessa Cervera Soriano3J. García-Castro4C. A. Fajardo5R. Alemany6Virotherapy and Gene Therapy Group, ProCure Program, Translational Research Laboratory, Instituto Catalan de Oncología-IDIBELL, Barcelona, SpainVirotherapy and Gene Therapy Group, ProCure Program, Translational Research Laboratory, Instituto Catalan de Oncología-IDIBELL, Barcelona, SpainServei d'Anatomia Patològica, Hospital Universitari Arnau de Vilanova i Institut de Recerca Biomèdica de Lleida, Lleida, SpainGenomics and Cytomics Unit, Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, SpainCellular Biotechnology Laboratory, Institute of Health Carlos III (ISCIII), Majadahonda, Madrid, SpainVirotherapy and Gene Therapy Group, ProCure Program, Translational Research Laboratory, Instituto Catalan de Oncología-IDIBELL, Barcelona, SpainVirotherapy and Gene Therapy Group, ProCure Program, Translational Research Laboratory, Instituto Catalan de Oncología-IDIBELL, Barcelona, SpainAntitumor efficacy of systemically administered oncolytic adenoviruses (OAdv) is limited due to diverse factors such as liver sequestration, neutralizing interactions in blood, elimination by the immune system, and physical barriers in tumors. It is therefore of clinical relevance to improve OAdv bioavailability and tumor delivery. Among the variety of tumor-targeting strategies, the use of stem cells and specifically bone marrow-derived mesenchymal stem cells (BM-MSCs) is of particular interest due to their tumor tropism and immunomodulatory properties. Nonetheless, the invasive methods to obtain these cells, the low number of MSCs present in the bone marrow, and their restricted in vitro expansion represent major obstacles for their use in cancer treatments, pointing out the necessity to identify an alternative source of MSCs. Here, we have evaluated the use of menstrual blood-derived mesenchymal stem cells (MenSCs) as cell carriers for regional delivery of an OAdv in the tumor. Our results indicate that MenSCs can be isolated without invasive methods, they have an increased proliferation rate compared to BM-MSCs, and they can be efficiently infected with different serotype 5-based capsid-modified adenoviruses, leading to viral replication and release. In addition, our in vivo studies confirmed the tumor-homing properties of MenSCs after regional administration.http://dx.doi.org/10.1155/2017/3615729
spellingShingle R. Moreno
L. A. Rojas
Felip Vilardell Villellas
Vanessa Cervera Soriano
J. García-Castro
C. A. Fajardo
R. Alemany
Human Menstrual Blood-Derived Mesenchymal Stem Cells as Potential Cell Carriers for Oncolytic Adenovirus
Stem Cells International
title Human Menstrual Blood-Derived Mesenchymal Stem Cells as Potential Cell Carriers for Oncolytic Adenovirus
title_full Human Menstrual Blood-Derived Mesenchymal Stem Cells as Potential Cell Carriers for Oncolytic Adenovirus
title_fullStr Human Menstrual Blood-Derived Mesenchymal Stem Cells as Potential Cell Carriers for Oncolytic Adenovirus
title_full_unstemmed Human Menstrual Blood-Derived Mesenchymal Stem Cells as Potential Cell Carriers for Oncolytic Adenovirus
title_short Human Menstrual Blood-Derived Mesenchymal Stem Cells as Potential Cell Carriers for Oncolytic Adenovirus
title_sort human menstrual blood derived mesenchymal stem cells as potential cell carriers for oncolytic adenovirus
url http://dx.doi.org/10.1155/2017/3615729
work_keys_str_mv AT rmoreno humanmenstrualbloodderivedmesenchymalstemcellsaspotentialcellcarriersforoncolyticadenovirus
AT larojas humanmenstrualbloodderivedmesenchymalstemcellsaspotentialcellcarriersforoncolyticadenovirus
AT felipvilardellvillellas humanmenstrualbloodderivedmesenchymalstemcellsaspotentialcellcarriersforoncolyticadenovirus
AT vanessacerverasoriano humanmenstrualbloodderivedmesenchymalstemcellsaspotentialcellcarriersforoncolyticadenovirus
AT jgarciacastro humanmenstrualbloodderivedmesenchymalstemcellsaspotentialcellcarriersforoncolyticadenovirus
AT cafajardo humanmenstrualbloodderivedmesenchymalstemcellsaspotentialcellcarriersforoncolyticadenovirus
AT ralemany humanmenstrualbloodderivedmesenchymalstemcellsaspotentialcellcarriersforoncolyticadenovirus